Bristol-Myers Squibb Co (BRM) Stock Price & News

Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban for people with atrial fibrillation; nivolumab, used to treat certain types of cancer; lenalidomide, used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes; abatacept, used to treat autoimmune diseases such as rheumatoid arthritis; pomalidomide, an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma; ipilimumab, to treat cancer; and luspatercept for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2025, 69% of the company's revenues came from the United States. The company is ranked 94th on the Fortune 500 and 173rd on the Forbes Global 2000. Wikipedia

About Bristol-Myers Squibb Co

CEOChris Boerner

Employees32,5 k

Founded1887

HeadquartersNew York Stad, New York, Verenigde State van Amerika

SectorPharmaceutical industry

Websitebms.com

All values in USD	Sep. 2025	Des. 2025	Mrt. 2026	Jun. 2026
Revenue	12,22 mjd	12,50 mjd	11,49 mjd	12,97 mjd
Cost of goods sold	3,31 mjd	3,51 mjd	3,41 mjd	3,71 mjd
Cost of revenue	3,31 mjd	3,51 mjd	3,41 mjd	3,71 mjd
Research and development expenses	2,43 mjd	2,56 mjd	2,24 mjd	2,54 mjd
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	1,79 mjd	2,09 mjd	1,61 mjd	1,82 mjd
Operating expense	5,05 mjd	5,47 mjd	4,28 mjd	4,80 mjd
Total operating expenses	8,36 mjd	8,98 mjd	7,69 mjd	8,51 mjd
Operating income	3,86 mjd	3,52 mjd	3,80 mjd	4,46 mjd
Other non operating income	529,00 m	544,00 m	125,00 m	106,00 m
EBT including unusual items	3,11 mjd	1,47 mjd	3,24 mjd	4,09 mjd
EBT excluding unusual items	4,07 mjd	3,86 mjd	3,65 mjd	4,35 mjd
Income tax expense	919,00 m	384,00 m	561,00 m	770,00 m
Effective tax rate	29,51%	26,12%	17,32%	18,84%
Other operating expenses	-	-	-	-
Net income	2,20 mjd	1,09 mjd	2,68 mjd	3,32 mjd
Net profit margin	18,01%	8,69%	23,30%	25,57%
Earnings per share	1,63	1,26	1,58	2,04
Interest and investment income	161,00 m	148,00 m	104,00 m	101,00 m
Interest expense	-482,00 m	-432,00 m	-406,00 m	-403,00 m
Net interest expenses	-321,00 m	-284,00 m	-302,00 m	-302,00 m
Depreciation and amortization charges	-	-	-	-
EBITDA	4,91 mjd	4,54 mjd	4,41 mjd	5,08 mjd
Gain or loss from assets sale	-9,00 m	-	-34,00 m	-142,00 m

Finance

Ask anything